Andreas Jung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Andreas Jung has a total of 587 co-authors. Here are the top co-authors by number of shared publications:
- Siobhan B. Carr
Paediatric Respiratory Medicine, Royal Brompton Hospital, London, UK
7 shared publications - Annalisa Orenti
Department of Clinical Sciences and Community Health, Dipartimento di Eccellenza 2023-2027, Laboratory of Medical Statistics, Biometry and Epidemiology “G.A. Maccacaro”, University of Milan, Milan, Italy
6 shared publications - Claudia Elisabeth Kuehni
Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland
5 shared publications Carla Colombo
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy
4 shared publications- Géraldine Daneau
Sciensano, BELGIUM
4 shared publications - Marco Salvatore
National Centre for Rare Diseases, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy
4 shared publications
Latest Publications
- 11 March 2026
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 25 (4) , 670-677
Outcomes of SARS-CoV-2 infection post-solid organ transplantation in the cystic fibrosis population
- 11 March 2026
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 25 (4) , 670-677
Outcomes of SARS-CoV-2 infection post-solid organ transplantation in the cystic fibrosis population
- Open Access
How well does spirometry capture the symptom range in primary ciliary dyskinesia? – a cross-sectional national study
Introduction: Patients with primary ciliary dyskinesia (PCD) present a variety of respiratory symptoms. Spirometry, particularly forced expiratory volume in 1 s (FEV1), is the most commonly used outcome measure in clinical follow-up, however, it is not known how well it captures the range of respiratory symptoms experienced by patients. Methods: We sent the FOLLOW-PCD questionnaire to all patients ≥14 years and parents of children, registered in the Swiss PCD Registry, asking about upper and lower respiratory symptoms. In patients who had a routine lung function done within a year of survey completion, we extracted data from clinical records and calculated spirometric indices z-scores based on the Global Lung Function Initiative references. We used linear regression to study associations between FEV1, forced vital capacity (FVC), FEV1/FVC and frequency of respiratory symptoms, adjusted for age, sex, and regular physiotherapy. Results: 64 out of 99 invited patients (67%) completed the survey; for 54 of them (median age 24 years, IQR 15-47; 50% females) we also had an FEV1 measurement (mean z-score - 2.29 [- 3.37 – −1.03]), with 2.2 months median time between survey and lung function test. Patients reporting wheeze (76%) had lower FEV1 and FEV1/FVC z-scores (FEV1 z-score for infrequent and frequent wheeze compared to no wheeze: −1.13 [95%CI −2.13 – −0.12] and −1.11 [−2.20 – - 0.20] respectively). Similarly patients reporting frequent shortness of breath (29.5%) had also lower FEV1 and FEV1/FVC z-scores (FEV1 z-score for frequent shortness of breath compared to no shortness of breath: −1.27 [−2.50 – −0.04]). We found no signs of association between reported nasal symptoms, snoring, cough, sputum production, and chest pain with FEV1, FVC or FEV1/FVC. Conclusion: In our study, self-reported wheeze and frequent shortness of breath were associated with lower FEV1 and FEV1/FVC, commonly used for patient follow-up. However, we need additional outcome measures e.g., lung clearance index, imaging outcomes, or upper airway assessments, together with regular and standardised assessment of patient-reported symptoms, to capture the range of respiratory morbidity patients with PCD experience in daily life and guide management successfully.
Open AccessHow well does spirometry capture the symptom range in primary ciliary dyskinesia? – a cross-sectional national study
Introduction: Patients with primary ciliary dyskinesia (PCD) present a variety of respiratory symptoms. Spirometry, particularly forced expiratory volume in 1 s (FEV1), is the most commonly used outcome measure in clinical follow-up, however, it is not known how well it captures the range of respiratory symptoms experienced by patients. Methods: We sent the FOLLOW-PCD questionnaire to all patients ≥14 years and parents of children, registered in the Swiss PCD Registry, asking about upper and lower respiratory symptoms. In patients who had a routine lung function done within a year of survey completion, we extracted data from clinical records and calculated spirometric indices z-scores based on the Global Lung Function Initiative references. We used linear regression to study associations between FEV1, forced vital capacity (FVC), FEV1/FVC and frequency of respiratory symptoms, adjusted for age, sex, and regular physiotherapy. Results: 64 out of 99 invited patients (67%) completed the survey; for 54 of them (median age 24 years, IQR 15-47; 50% females) we also had an FEV1 measurement (mean z-score - 2.29 [- 3.37 – −1.03]), with 2.2 months median time between survey and lung function test. Patients reporting wheeze (76%) had lower FEV1 and FEV1/FVC z-scores (FEV1 z-score for infrequent and frequent wheeze compared to no wheeze: −1.13 [95%CI −2.13 – −0.12] and −1.11 [−2.20 – - 0.20] respectively). Similarly patients reporting frequent shortness of breath (29.5%) had also lower FEV1 and FEV1/FVC z-scores (FEV1 z-score for frequent shortness of breath compared to no shortness of breath: −1.27 [−2.50 – −0.04]). We found no signs of association between reported nasal symptoms, snoring, cough, sputum production, and chest pain with FEV1, FVC or FEV1/FVC. Conclusion: In our study, self-reported wheeze and frequent shortness of breath were associated with lower FEV1 and FEV1/FVC, commonly used for patient follow-up. However, we need additional outcome measures e.g., lung clearance index, imaging outcomes, or upper airway assessments, together with regular and standardised assessment of patient-reported symptoms, to capture the range of respiratory morbidity patients with PCD experience in daily life and guide management successfully.
- Open Access
- 26 August 2024
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (5) , 815-822
Impact of COVID-19 infection on lung function and nutritional status amongst individuals with cystic fibrosis: A global cohort study
- 26 August 2024
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (5) , 815-822
Open AccessImpact of COVID-19 infection on lung function and nutritional status amongst individuals with cystic fibrosis: A global cohort study
- Open Access
- 22 August 2024
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (1)
Variability in disease severity among cystic fibrosis patients carrying residual-function variants: data from the European Cystic Fibrosis Society Patient Registry
Background: People with cystic fibrosis (CF) variants that exhibit residual function (RF) of the CF transmembrane conductance regulator are considered to have a milder disease; however, the spectrum of CF phenotype within the different RF variants has not been extensively investigated. The aim of the present study was to characterise the spectrum of CF disease severity in people with CF (pwCF) carrying different RF variants, using the European Cystic Fibrosis Society Patient Registry (ECFSPR) data.Methods: A retrospective cross-sectional and longitudinal cohort study included data from the ECFSPR during 2008–2016. Demographic and clinical characteristics of pwCF carrying different RF variants were compared with the characteristics of pwCF who are homozygous for F508del. Among those with RF, a distinction was made between pwCF carrying class IV or class V variants and pwCF carrying specific RF variants.Results: Out of 56 701 pwCF in the ECFSPR, 6192 carried RF variants and 22 766 were homozygous for F508del. Class IV/F508del variants were associated with a milder course than class V/F508del; both were milder than pwCF homozygous for F508del. Forced expiratory volume in 1 s % predicted (FEV1pp) declined in childhood in all groups. For adults, the hazard ratio of death for class V/F508delversusclass IV/F508del was 2.14 (95% confidence interval 0.99–4.63, p=0.052). PwCF carrying 3849+10 kb C→T/F508del and pwCF carrying R334W/F508del had age-specific FEV1pp and chronic bacterial colonisation similar to those of pwCF homozygous for F508del.Conclusion: There is a wide spectrum of disease severity between the different RF variants. Some, such as those carrying 3849+10 kb C→T, have severe disease, similar to that of pwCF homozygous for F508del.
- 22 August 2024
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (1)
Open AccessVariability in disease severity among cystic fibrosis patients carrying residual-function variants: data from the European Cystic Fibrosis Society Patient Registry
Background: People with cystic fibrosis (CF) variants that exhibit residual function (RF) of the CF transmembrane conductance regulator are considered to have a milder disease; however, the spectrum of CF phenotype within the different RF variants has not been extensively investigated. The aim of the present study was to characterise the spectrum of CF disease severity in people with CF (pwCF) carrying different RF variants, using the European Cystic Fibrosis Society Patient Registry (ECFSPR) data.Methods: A retrospective cross-sectional and longitudinal cohort study included data from the ECFSPR during 2008–2016. Demographic and clinical characteristics of pwCF carrying different RF variants were compared with the characteristics of pwCF who are homozygous for F508del. Among those with RF, a distinction was made between pwCF carrying class IV or class V variants and pwCF carrying specific RF variants.Results: Out of 56 701 pwCF in the ECFSPR, 6192 carried RF variants and 22 766 were homozygous for F508del. Class IV/F508del variants were associated with a milder course than class V/F508del; both were milder than pwCF homozygous for F508del. Forced expiratory volume in 1 s % predicted (FEV1pp) declined in childhood in all groups. For adults, the hazard ratio of death for class V/F508delversusclass IV/F508del was 2.14 (95% confidence interval 0.99–4.63, p=0.052). PwCF carrying 3849+10 kb C→T/F508del and pwCF carrying R334W/F508del had age-specific FEV1pp and chronic bacterial colonisation similar to those of pwCF homozygous for F508del.Conclusion: There is a wide spectrum of disease severity between the different RF variants. Some, such as those carrying 3849+10 kb C→T, have severe disease, similar to that of pwCF homozygous for F508del.
- 22 February 2024
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (3) , 388-397
ECFS standards of care on CFTR-related disorders: Towards a comprehensive program for affected individuals
- 22 February 2024
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (3) , 388-397
ECFS standards of care on CFTR-related disorders: Towards a comprehensive program for affected individuals
- Open Access
- 22 November 2023
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (3) , 506-511
Data accuracy, consistency and completeness of the national Swiss cystic fibrosis patient registry: Lessons from an ECFSPR data quality project
- 22 November 2023
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (3) , 506-511
Open AccessData accuracy, consistency and completeness of the national Swiss cystic fibrosis patient registry: Lessons from an ECFSPR data quality project
- Open Access
- 3 November 2023
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (2) , 354-363
A multinational report on SARS-CoV-2 infection outcomes in people with CF and Aspergillus infection or ABPA
- 3 November 2023
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 23 (2) , 354-363
Open AccessA multinational report on SARS-CoV-2 infection outcomes in people with CF and Aspergillus infection or ABPA
- Open Access
- 23 February 2023
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 9 (3)
Risk factors for forced expiratory volume in 1 s decline in European patients with cystic fibrosis: data from the European Cystic Fibrosis Society Patient Registry
Aim: To examine the trajectory of forced expiratory volume in 1 s (FEV1) using data from the European Cystic Fibrosis Society patient registry (ECFPR) collected from 2008 to 2016,i.e.the era before highly effective modulator therapy (HEMT). We evaluated risk factors for FEV1decline.Methods: The study population included patients with a confirmed diagnosis of cystic fibrosis recorded in the ECFPR (2008–2016). The evolution of FEV1% predicted (%FEV1) with age, and the yearly change in %FEV1were evaluated. Risk factors considered were cystic fibrosis transmembrane conductance regulator (CFTR) mutation class, gender, age at diagnosis, neonatal screening, meconium ileus, sweat chloride concentration at diagnosis and country's income level.Results: We used 199 604 FEV1recordings from 38 734 patients. The fastest decline was seen during puberty and in patients diagnosed before the age of 10 years. Males had a higher %FEV1, but a higher yearly %FEV1loss between the ages of 15 and 25 years. We showed stabilisation and even improvement in %FEV1over age in adults with a class IIICFTRmutation, but a steady decline in patients homozygous for F508del or with both mutations of classes I/II. A faster decline in %FEV1was found in patients from low-income countries compared to a similar %FEV1evolution in patients from middle- and high-income countries.Conclusions: These longitudinal FEV1data reflect the reality of cystic fibrosis across Europe in the era pre-HEMT, and can serve as baseline for comparison with the post-HEMT era. The similar evolution in middle- and high-income countries underlines opportunities for low-income countries.
- 23 February 2023
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 9 (3)
Open AccessRisk factors for forced expiratory volume in 1 s decline in European patients with cystic fibrosis: data from the European Cystic Fibrosis Society Patient Registry
Aim: To examine the trajectory of forced expiratory volume in 1 s (FEV1) using data from the European Cystic Fibrosis Society patient registry (ECFPR) collected from 2008 to 2016,i.e.the era before highly effective modulator therapy (HEMT). We evaluated risk factors for FEV1decline.Methods: The study population included patients with a confirmed diagnosis of cystic fibrosis recorded in the ECFPR (2008–2016). The evolution of FEV1% predicted (%FEV1) with age, and the yearly change in %FEV1were evaluated. Risk factors considered were cystic fibrosis transmembrane conductance regulator (CFTR) mutation class, gender, age at diagnosis, neonatal screening, meconium ileus, sweat chloride concentration at diagnosis and country's income level.Results: We used 199 604 FEV1recordings from 38 734 patients. The fastest decline was seen during puberty and in patients diagnosed before the age of 10 years. Males had a higher %FEV1, but a higher yearly %FEV1loss between the ages of 15 and 25 years. We showed stabilisation and even improvement in %FEV1over age in adults with a class IIICFTRmutation, but a steady decline in patients homozygous for F508del or with both mutations of classes I/II. A faster decline in %FEV1was found in patients from low-income countries compared to a similar %FEV1evolution in patients from middle- and high-income countries.Conclusions: These longitudinal FEV1data reflect the reality of cystic fibrosis across Europe in the era pre-HEMT, and can serve as baseline for comparison with the post-HEMT era. The similar evolution in middle- and high-income countries underlines opportunities for low-income countries.
- 22 September 2022
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 60 (5) , 2103112
Feasibility of unsedated lung MRI in young children with cystic fibrosis
- 22 September 2022
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 60 (5) , 2103112
Feasibility of unsedated lung MRI in young children with cystic fibrosis
- 13 June 2022
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 21 (4) , e221-e231
Factors associated with clinical progression to severe COVID-19 in people with cystic fibrosis: A global observational study
- 13 June 2022
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 21 (4) , e221-e231
Factors associated with clinical progression to severe COVID-19 in people with cystic fibrosis: A global observational study